# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Sol-Gel Technologies (NASDAQ:SLGL) with a Buy and maintains $6...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Sol-Gel Technologies (NASDAQ:SLGL) with a Buy and lowers the pr...
Under the terms of the agreement, Beimei purchases and licenses rights to exclusively commercialize TWYNEO in these territories...
On March 26, 2024, Arcutis Biotherapeutics initiated a patent infringement action in the U.S. District Court for the District o...
Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a disc...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Sol-Gel Technologies (NASDAQ:SLGL) with a Buy and lowers the pr...
Sol-Gel Technologies (NASDAQ:SLGL) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of ...